Robeco Institutional Asset Management B.V. Boosts Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Robeco Institutional Asset Management B.V. raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 0.2% during the first quarter, Holdings Channel reports. The fund owned 4,387,326 shares of the biopharmaceutical company’s stock after buying an additional 8,879 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Bristol Myers Squibb were worth $267,583,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Polar Asset Management Partners Inc. purchased a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $16,651,000. Avaii Wealth Management LLC raised its stake in shares of Bristol Myers Squibb by 590.9% in the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 67,221 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Bristol Myers Squibb by 1.4% in the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company’s stock valued at $3,967,000 after buying an additional 869 shares during the period. Shorepoint Capital Partners LLC lifted its position in shares of Bristol Myers Squibb by 2.2% during the 4th quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company’s stock valued at $3,305,000 after buying an additional 1,248 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Bristol Myers Squibb by 17.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company’s stock worth $33,582,000 after acquiring an additional 80,087 shares during the period. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Down 0.6%

BMY stock opened at $46.73 on Thursday. The company’s 50 day moving average is $48.01 and its 200 day moving average is $54.11. The stock has a market cap of $95.10 billion, a price-to-earnings ratio of 17.50, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) EPS. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.31%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Argus raised shares of Bristol Myers Squibb to a “hold” rating in a report on Friday, April 25th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.